Sobering, keeps you focused…..
• Unigene (UGNE: OTC) - $41m market cap ($114m enterprise value);licensed oral calcitonin formulation to Tarsa (private) for osteoporosis
• NPS (NPSP: NASDAQ) - $617m market cap; 2 PhIII therapeutic peptides for rare diseases, including proprietary recombinant PTH for hypothyroidism
• Acrux (ACR: ASX) - $668m market cap; out-licenses transdermal technologies/products
• Lexicon Pharma (LXRX: NASDAQ) - $779m market cap; novel peptides for target diseases including autoimmune diseases
BNE as at 30/4/2012 Market Capitalization: $2.3 Million vs $5.3 Million enterprise value. Current market cap $1.8m undiluted
• Discussions with multiple multinational & regional firms:
– Product profiles are attractive partnering prospects
– Requested specific additional data in some cases
– Active discussions
Flux
looking good, page-13
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $588.2M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.5¢ | $1.302M | 3.974M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 713153 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 215665 | 6 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |